Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HINT1 | P49773 | 6/20 | 0.47 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.46 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
| ▸ | GSK3A | P49840 | 2/20 | 0.45 |
| ▸ | RPS6KA3 | P51812 | 2/20 | 0.45 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.45 |
| ▸ | NT5E | P21589 | 1/20 | 0.43 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.43 |
| ▸ | PNP | P00491 | 1/20 | 0.42 |
| ▸ | TGM2 | P21980 | 1/20 | 0.41 |
| ▸ | KRAS | P01116 | 5/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7063499 | 0.92 | HINT1 (0.53) | HINT1TAS1R3TAS1R1HPGDGSK3A | |
| SCHEMBL7063503 | 0.92 | HINT1 (0.53) | HINT1TAS1R3TAS1R1HPGDGSK3A | |
| SCHEMBL5507306 | 0.91 | HINT1 (0.44) | HINT1TAS1R3TAS1R1HPGDGSK3A | |
| SCHEMBL5504409 | 0.88 | HINT1 (0.41) | HINT1TAS1R3TAS1R1HPGDGSK3A | |
| SCHEMBL6468412 | 0.85 | HINT1 (0.64) | HINT1GSK3ARPS6KA3MAPK14NT5E | |
| SCHEMBL17936222 | 0.85 | HINT1 (0.64) | HINT1GSK3ARPS6KA3MAPK14NT5E | |
| SCHEMBL17198404 | 0.84 | HINT1 (0.54) | HINT1TAS1R3TAS1R1HPGDGSK3A | |
| SCHEMBL881724 | 0.83 | NT5E (0.57) | HINT1TAS1R3TAS1R1GSK3ARPS6KA3 | |
| SCHEMBL16264223 | 0.80 | TAS1R3 (0.44) | HINT1TAS1R3TAS1R1HPGDGSK3A | |
| SCHEMBL14364934 | 0.80 | TAS1R3 (0.44) | HINT1TAS1R3TAS1R1HPGDGSK3A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0977767-B1 | AMINOOXY-MODIFIED OLIGONUCLEOTIDES | ISIS PHARMACEUTICALS INC (US) | 2007-09-19 | — | — | EP | disclosed |
| US-6849723-B2 | Oligonucleotide analogs having modified dimers | ISIS PHARMACEUTICALS, INC. (US) | 2005-02-01 | — | — | US | disclosed |
| US-20030088079-A1 | AMINOOXY-MODIFIED NUCLEOSIDIC COMPOUNDS AND OLIGOMERIC COMPOUNDS PREPARED THEREFROM | IONIS PHARMACEUTICALS, INC. | 2003-05-08 | — | — | US | disclosed |
| EP-0977767-A4 | AMINOOXY-MODIFIED OLIGONUCLEOTIDES | ISIS PHARMACEUTICALS INC (US) | 2003-04-23 | — | — | EP | disclosed |
| US-6420549-B1 | NUCLEOTIDE SEQUENCES FOR USE AS TOOLS IN GENETIC ENGINEERING AND CONTROLLING TRANSLATION | ISIS PHARMACEUTICALS, INC. | 2002-07-16 | — | — | US | disclosed |
| US-6194598-B1 | Aminooxy-modified oligonucleotide synthetic intermediates | ISIS PHARMACEUTICALS, INC. | 2001-02-27 | — | — | US | disclosed |
| US-6172209-B1 | MOLECULAR HYBRIDIZATION, GENETIC ENGINEERING; NUCLEASE RESISTANCE | ISIS PHARMACEUTICALS INC. | 2001-01-09 | — | — | US | disclosed |
| US-6127533-A | SPECIFICALLY HYBRIDIZABLE WITH A SELECTED SEQUENCE OF RNA OR DNA; DIAGNOSIS OF DISEASES | ISIS PHARMACEUTICALS, INC. (US) | 2000-10-03 | — | — | US | disclosed |
| EP-0977767-A1 | AMINOOXY-MODIFIED OLIGONUCLEOTIDES | ISIS PHARMACEUTICALS, INC. (US) | 2000-02-09 | — | — | EP | disclosed |
| WO-1998035978-A9 | AMINOOXY-MODIFIED OLIGONUCLEOTIDES | — | 1999-01-14 | — | — | WO | disclosed |
| WO-1998035978-A1 | AMINOOXY-MODIFIED OLIGONUCLEOTIDES | ISIS PHARMACEUTICALS, INC. (US) | 1998-08-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030088079-A1 | AMINOOXY-MODIFIED NUCLEOSIDIC COMPOUNDS AND OLIGOMERIC COMPOUNDS PREPARED THEREFROM | HNRNPM, RNASEH1, HNRNPF | HINT1 479/4885TAS1R3 4572/4885TAS1R1 4668/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.